Evidence map›Paper›PMID 26101915›Full record

ArticleOncotarget2015

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, Edmund A Rossi, Robert M Sharkey

Erratum issued Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04617522 (A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment), which is not on this map. Cited by 266 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed, 5 pooled it
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04617522 phase1recruitingnot on this mapstarted 2021, after this paper: background citation

A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

TypeinterventionalSponsorGilead SciencesRan2021 to 2026Enrolled30ConditionsAdvanced or Metastatic Solid Tumor, Liver FailureArmsSacituzumab Govitecan-hziy
3 · Its place in the literature

Who cites it

266 citing papers in PubMed, 5 syntheses or guidelines pooled it, 458 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Sacituzumab govitecan in HRNature medicine · 2024
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Pegylated liposomal doxorubicin (DuomeisuBreast cancer research and treatment · 2023
    Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

206 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

David M GoldenbergImmunomedics, Inc., Morris Plains, NJ, USA.
Thomas M CardilloImmunomedics, Inc., Morris Plains, NJ, USA.
Serengulam V GovindanImmunomedics, Inc., Morris Plains, NJ, USA.
Edmund A RossiImmunomedics, Inc., Morris Plains, NJ, USA.
Robert M SharkeyImmunomedics, Inc., Morris Plains, NJ, USA.
Immunomedics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. In vitro and in vivo studies show enhanced efficacy, while there is a gradual release of SN-38 that contributes to the overall effect. IMMU-132 is most efficacious at a high drug:antibody ratio (DAR) of 7.6:1, which does not affect binding and pharmacokinetics. It targets up to 136-fold more SN-38 to a human cancer xenograft than irinotecan, SN-38's prodrug. IMMU-132 delivers SN-38 in its most active, non-glucuronidated form, which may explain the lower frequency of severe diarrhea than with irinotecan. Thus, this ADC, carrying a moderately-toxic drug targeting Trop-2 represents a novel cancer therapeutic that is showing promising activity in patients with several metastatic cancer types, including triple-negative breast cancer, non-small-cell and small-cell lung cancers.

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedAntigens, NeoplasmCamptothecinCell Adhesion MoleculesCell Line, TumorFemaleHumansImmunoconjugatesIrinotecanMCF-7 CellsMice, NudeMolecular Targeted TherapyTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedAntigens, NeoplasmCamptothecinCell Adhesion MoleculesImmunoconjugatesIrinotecansacituzumab govitecanTACSTD2 protein, humanantibody-drug conjugateSN-38solid cancerstriple-negative breast cancerTrop-2

Identifiers

PMID26101915
PMCPMC4673178
OpenAlexW1486001319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.